Novo Nordisk raised its 2026 profit guidance Wednesday after Wegovy pill sales crushed expectations in the first quarter. The oral weight-loss drug generated 2.26 billion Danish kroner in sales, nearly double analyst estimates of 1.16 billion kroner. First-quarter revenue jumped 32 percent on a constant currency basis to 15.2 billion dollars, while operating profit surged 65 percent. The company now projects adjusted sales and profit to contract between 4 and 12 percent, an improvement from prior guidance of 5 to 13 percent decline. Wegovy commands 65 percent of all new weight-loss drug prescriptions in the U.S., with 1.3 million prescriptions filled in the quarter. CEO Mike Doustdar highlighted double-digit growth momentum despite competition from Eli Lilly's Mounjaro.
